PIs

Question 1

Atazanavir

Answer 1

PIs

MOA: block proteolytic cleavage of protein precursors that are necessary for the production of infectious particles

AE:
Class:
-Metabolic abnormalities (Less with atazanavir)
=”protease pouch” = hyperlipidemia, hyperglycemia, fat redistribution
-Hepatotoxicity (increases LFT)
-Special: Hyperbilirubinemia (inhibits UDP-glucuronyl-tranferase)
Class Interactions: CYP inhibitors

Other Characteristics:
-boosted with ritonavir or cobicistat

Question 2

Darunavir

Answer 2

PIs

MOA: block proteolytic cleavage of protein precursors that are necessary for the production of infectious particles

AE:
Class:
-Metabolic abnormalities (Less with atazanavir)
=”protease pouch” = hyperlipidemia, hyperglycemia, fat redistribution
-Hepatotoxicity (increases LFT)

Class Interactions: CYP inhibitors

Other Characteristics:
-boosted with ritonavir or cobicistat

Question 3

Ritonavir

Answer 3

PIs

***Only used as “booster”

MOA: block proteolytic cleavage of protein precursors that are necessary for the production of infectious particles

AE:
Class:
-Metabolic abnormalities (Less with atazanavir)
=”protease pouch” = hyperlipidemia, hyperglycemia, fat redistribution
-Hepatotoxicity (increases LFT)

Class Interactions: CYP inhibitors

Other Characteristics:
-boosted with ritonavir or cobicistat

Question 4

Nelfinavir

Answer 4

PIs

MOA: block proteolytic cleavage of protein precursors that are necessary for the production of infectious particles

AE:
Class:
-Metabolic abnormalities (Less with atazanavir)
=”protease pouch” = hyperlipidemia, hyperglycemia, fat redistribution
-Hepatotoxicity (increases LFT)

Class Interactions: CYP inhibitors

Other Characteristics:
-only PI that does not require boosting

Question 5

Indinavir

Answer 5

PIs

MOA: block proteolytic cleavage of protein precursors that are necessary for the production of infectious particles

AE:
Class:
-Metabolic abnormalities (Less with atazanavir)
=”protease pouch” = hyperlipidemia, hyperglycemia, fat redistribution
-Hepatotoxicity (increases LFT)

Class Interactions: CYP inhibitors

Other Characteristics:
-boosted with ritonavir or cobicistat